Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Purine nucleoside phosphorylase (DeoD-type) from Escherichia coli is a hexameric enzyme (EC 2.4.2.1) that catalyzes the reversible phosphorolysis of purine ribonucleosides and 2′-deoxypurine nucleosides, yielding free purine bases and ribose 1-phosphate[1][3][4]. It plays a critical role in the purine salvage pathway, providing essential bases for DNA and RNA synthesis[1][4]. E. coli PNP is structurally and mechanistically distinct from mammalian PNPs; while both catalyze similar reactions, E. coli PNP is a hexamer with broader substrate specificity, unlike the trimeric mammalian enzymes[3]. This difference is harnessed in gene therapy strategies, where E. coli PNP can activate specific prodrugs that are inert to mammalian PNP, conferring selectivity for cells expressing the bacterial enzyme[3]. Acyclovir, an antiviral agent, is a known substrate analog for structural studies[1].
Catalyzes phosphorolysis of N-glycosidic bond in purine (deoxy)ribonucleosides using orthophosphate, yielding free purine bases and (deoxy)ribose-1-phosphate[1][2][3][4]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purine nucleoside phosphorylase (DeoD-type) (PNP).